Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values

Antonio Tito Fojo; Alfred I. Neugut

doi:10.1093/oncolo/oyad203

Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values

Vagelos College of Physicians and Surgeons

Résultat de recherche › examen par les pairs

Langue d'origine	English
Pages (de-à)	102-105
Nombre de pages	4
Journal	Oncologist
Volume	29
Numéro de publication	2
DOI	https://doi.org/10.1093/oncolo/oyad203
Statut de publication	Published - févr. 2024

Financement

Alfred I. Neugut reported consulting for Otsuka, GlaxoSmithKline, Value Analytics, United Biosource Corporation, and Eisai, grant support from Otsuka, medical advisory board for EHE International, and scientific advisory board for Organon. Antonio Tito Fojo indicated no financial relationships.

Bailleurs de fonds	Numéro du bailleur de fonds
Otsuka America
Eisai

ASJC Scopus Subject Areas

General Medicine

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1093/oncolo/oyad203

Autres fichiers et liens

Citer

@article{87a69bf6cd5d48d8865914a7dfb23040,

title = "Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values",

author = "Fojo, {Antonio Tito} and Neugut, {Alfred I.}",

year = "2024",

month = feb,

doi = "10.1093/oncolo/oyad203",

language = "English",

volume = "29",

pages = "102--105",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "2",

}

TY - JOUR

T1 - Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values

AU - Fojo, Antonio Tito

AU - Neugut, Alfred I.

PY - 2024/2

Y1 - 2024/2

UR - http://www.scopus.com/inward/record.url?scp=85183990426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85183990426&partnerID=8YFLogxK

U2 - 10.1093/oncolo/oyad203

DO - 10.1093/oncolo/oyad203

M3 - Comment/debate

C2 - 37682036

AN - SCOPUS:85183990426

SN - 1083-7159

VL - 29

SP - 102

EP - 105

JO - Oncologist

JF - Oncologist

IS - 2

ER -